Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
28.00
-0.88 (-3.05%)
Oct 31, 2024, 4:00 PM EDT - Market closed
Company Description
Oruka Therapeutics, Inc., a biotechnology company, develops novel biologics for the treatment of chronic skin diseases.
Its lead products include ORKA-001 that targets p19 subunit of interleukin-23 (IL-23p19); and ORKA-002 that targets interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of psoriasis psoriatic arthritis, and other inflammatory diseases.
The company is based in Waltham, Massachusetts.
Oruka Therapeutics, Inc.
| Country | United States |
| Founded | 2004 |
| CEO | Lawrence Klein |
Contact Details
Address: Building 23, Suite 105 Waltham, Massachusetts 02453 United States | |
| Website | orukatx.com |
Stock Details
| Ticker Symbol | ORKA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000907654 |
| ISIN Number | US6876041087 |
| Employer ID | 36-3855489 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Lawrence Klein | Chief Executive Officer |
| Arjun Agarwal | Chief Financial Officer |
| Laura Sandler | Chief Operating Officer |
| Alan Lada | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 18, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 7, 2024 | PRE 14A | Other preliminary proxy statements |
| Oct 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 4, 2024 | 8-K | Current Report |
| Sep 13, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 13, 2024 | 8-K | Current Report |
| Sep 6, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 5, 2024 | 8-K | Current Report |
| Aug 27, 2024 | 425 | Filing |